• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Risk factors for fractures following liver transplantation: a population-based cohort study.肝移植后骨折的风险因素:基于人群的队列研究。
Ann Med. 2023 Dec;55(1):2230871. doi: 10.1080/07853890.2023.2230871.
2
Risk Factors for Fractures in Renal Transplantation: A Population-Based Cohort Study.肾移植中骨折的危险因素:一项基于人群的队列研究。
Am J Nephrol. 2023;54(11-12):498-507. doi: 10.1159/000533125. Epub 2023 Oct 2.
3
Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.西罗莫司和他克莫司对伴有或不伴有丙型肝炎病毒的肝移植受者死亡率和移植物丢失的影响:对移植受者科学注册数据库的分析。
Liver Transpl. 2012 Sep;18(9):1029-36. doi: 10.1002/lt.23479.
4
Characterization and Predictors of Fractures Following Hematopoietic Stem Cell Transplantation.造血干细胞移植后骨折的特征及预测因素。
J Clin Endocrinol Metab. 2024 Oct 15;109(11):e2100-e2109. doi: 10.1210/clinem/dgae042.
5
Everolimus: a guide to its use in liver transplantation.依维莫司:在肝移植中的应用指南。
BioDrugs. 2013 Aug;27(4):407-11. doi: 10.1007/s40259-013-0041-6.
6
A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.一项关于原位肝移植受者从基于他克莫司的免疫抑制转换为基于西罗莫司的免疫抑制的回顾性研究。
Exp Clin Transplant. 2008 Jun;6(2):113-7.
7
High risk of osteoporosis and fracture following solid organ transplantation: a population-based study.实体器官移植后骨质疏松症和骨折的高风险:一项基于人群的研究。
Front Endocrinol (Lausanne). 2023 May 23;14:1167574. doi: 10.3389/fendo.2023.1167574. eCollection 2023.
8
Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation.实体器官移植后肝细胞癌的发病率及危险因素
Transplantation. 2008 Sep 27;86(6):784-90. doi: 10.1097/TP.0b013e3181837761.
9
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.肝移植术后慢性肾功能不全患者由钙调磷酸酶抑制剂转换为依维莫司后肾功能的改善。
Liver Transpl. 2009 Dec;15(12):1792-7. doi: 10.1002/lt.21920.
10
Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.依维莫司治疗肝移植后抗丙型肝炎病毒治疗相关自身免疫性肝炎的有效性和安全性:三例病例报告
Transplant Proc. 2011 Jul-Aug;43(6):2233-6. doi: 10.1016/j.transproceed.2011.05.028.

引用本文的文献

1
Results of the implementation of a multidisciplinary care protocol for preventing fragility fractures following liver transplantation.实施多学科护理方案预防肝移植后脆性骨折的结果。
Osteoporos Int. 2025 May 22. doi: 10.1007/s00198-025-07525-x.
2
The Incidence of Osteoporosis in Hepatocellular Carcinoma Patients Under 65: A Retrospective Cohort Study.65岁以下肝细胞癌患者骨质疏松症的发病率:一项回顾性队列研究
Cureus. 2025 Mar 12;17(3):e80490. doi: 10.7759/cureus.80490. eCollection 2025 Mar.
3
Emerging role of liver-bone axis in osteoporosis.肝-骨轴在骨质疏松症中的新作用
J Orthop Translat. 2024 Sep 4;48:217-231. doi: 10.1016/j.jot.2024.07.008. eCollection 2024 Sep.
4
Risk factors for fractures following liver transplantation: a population-based cohort study.肝移植后骨折的危险因素:一项基于人群的队列研究。
Ann Med. 2023;55(2):2272723. doi: 10.1080/07853890.2023.2272723. Epub 2023 Oct 29.

本文引用的文献

1
Risk of fractures and subsequent mortality in non-alcoholic fatty liver disease: A nationwide population-based cohort study.非酒精性脂肪性肝病患者骨折风险及后续死亡率:一项基于全国人群的队列研究。
J Intern Med. 2022 Sep;292(3):492-500. doi: 10.1111/joim.13497. Epub 2022 Apr 19.
2
Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.激素失衡导致的骨质疏松症:雌激素缺乏和糖皮质激素过度使用对骨代谢的影响概述。
Int J Mol Sci. 2022 Jan 25;23(3):1376. doi: 10.3390/ijms23031376.
3
Bone Disease and Liver Transplantation: A Review.骨病与肝移植:综述。
Transplant Proc. 2021 Sep;53(7):2346-2353. doi: 10.1016/j.transproceed.2021.07.049. Epub 2021 Aug 20.
4
Bisphosphonate therapy after liver transplant improves bone mineral density and reduces fracture rates: an updated systematic review and meta-analysis.肝移植后双膦酸盐治疗可改善骨密度并降低骨折率:一项更新的系统评价和荟萃分析。
Transpl Int. 2021 Aug;34(8):1386-1396. doi: 10.1111/tri.13887. Epub 2021 Jul 1.
5
Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.基于电子健康档案的 NAFLD 研究中的行政编码:专家小组共识声明。
Hepatology. 2021 Jul;74(1):474-482. doi: 10.1002/hep.31726. Epub 2021 Jun 22.
6
Vitamin K and Osteoporosis.维生素 K 与骨质疏松症。
Nutrients. 2020 Nov 25;12(12):3625. doi: 10.3390/nu12123625.
7
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.糖皮质激素性骨质疏松症的发病机制与治疗选择。
Nat Rev Endocrinol. 2020 Aug;16(8):437-447. doi: 10.1038/s41574-020-0341-0. Epub 2020 Apr 14.
8
Osteoporosis in cirrhotics before and after liver transplantation: relation with malnutrition and inflammatory status.肝硬化患者肝移植前后的骨质疏松症:与营养不良和炎症状态的关系。
Scand J Gastroenterol. 2020 Mar;55(3):354-361. doi: 10.1080/00365521.2020.1735507. Epub 2020 Mar 17.
9
Bone Diseases in Patients with Chronic Liver Disease.慢性肝病患者的骨骼疾病。
Int J Mol Sci. 2019 Aug 31;20(17):4270. doi: 10.3390/ijms20174270.
10
Glucocorticoid-Induced Osteoporosis.糖皮质激素性骨质疏松症
N Engl J Med. 2019 Apr 4;380(14):1378-1379. doi: 10.1056/NEJMc1901239.

肝移植后骨折的风险因素:基于人群的队列研究。

Risk factors for fractures following liver transplantation: a population-based cohort study.

机构信息

Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.

Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

出版信息

Ann Med. 2023 Dec;55(1):2230871. doi: 10.1080/07853890.2023.2230871.

DOI:10.1080/07853890.2023.2230871
PMID:37455447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10353320/
Abstract

BACKGROUND

Liver transplant recipients have an increased risk of osteoporosis and fractures. The aim of this study was to identify risk factors for fractures after liver transplant in a Taiwanese population.

METHODS

We identified newly diagnosed liver transplant recipients from the National Health Insurance Research Database in Taiwan between 2003 and 2015. Risk factors of post-transplant fractures were analyzed using a Cox proportional hazards model.

RESULTS

A total of 4821 patients underwent liver transplantation, of whom 419 (8.7%) had post-transplant fractures. Independent predictors of post-transplant fractures were age ≥65 years at transplantation (hazard ratio (HR): 1.566; 95% confidence interval (CI) 1.122-2.186), female sex (HR: 1.648; 95% CI 1.319-2.057), fractures within 1 year prior to transplant (HR: 3.664; 95% CI 2.503-5.364), hepatitis C carriers (HR: 1.594; 95% CI 1.289-1.970), alcoholism (HR: 1.557; 95% CI 1.087-2.230) and daily prednisolone dose >1.61-3.78 mg/day (HR: 1.354; 95% CI 1.005-1.824), >3.78-9.18 mg (HR: 4.182; 95% CI 3.155-5.544) and >9.18 mg (HR: 13.334; 95% CI 9.506-18.703). Post-transplant fractures were inversely correlated with tacrolimus (HR: 0.617; 95% CI 0.417-0.913) and sirolimus/everolimus (HR: 0.504; 95% CI 0.391-0.650) treatment.

CONCLUSIONS

The liver transplant recipients, and especially those who were aged ≥65 years, female, hepatitis C carriers, had a history of fractures within 1 year prior to transplant, alcoholism, and higher daily prednisolone dose were associated with an increased risk of post-transplant fractures. Conversely, the use of tacrolimus and sirolimus/everolimus was associated with a decreased risk of fractures.

摘要

背景

肝移植受者骨质疏松症和骨折的风险增加。本研究的目的是在台湾人群中确定肝移植后骨折的危险因素。

方法

我们从台湾 2003 年至 2015 年的全民健康保险研究数据库中确定了新诊断的肝移植受者。使用 Cox 比例风险模型分析移植后骨折的危险因素。

结果

共有 4821 名患者接受了肝移植,其中 419 名(8.7%)发生了移植后骨折。移植后骨折的独立预测因素为:移植时年龄≥65 岁(风险比(HR):1.566;95%置信区间(CI):1.122-2.186)、女性(HR:1.648;95%CI:1.319-2.057)、移植前 1 年内有骨折史(HR:3.664;95%CI:2.503-5.364)、丙型肝炎携带者(HR:1.594;95%CI:1.289-1.970)、酗酒(HR:1.557;95%CI:1.087-2.230)和每日泼尼松剂量>1.61-3.78mg/d(HR:1.354;95%CI:1.005-1.824)、>3.78-9.18mg(HR:4.182;95%CI:3.155-5.544)和>9.18mg(HR:13.334;95%CI:9.506-18.703)。移植后骨折与他克莫司(HR:0.617;95%CI:0.417-0.913)和西罗莫司/依维莫司(HR:0.504;95%CI:0.391-0.650)治疗呈负相关。

结论

肝移植受者,尤其是年龄≥65 岁、女性、丙型肝炎携带者、移植前 1 年内有骨折史、酗酒、每日泼尼松剂量较高者,发生移植后骨折的风险增加。相反,使用他克莫司和西罗莫司/依维莫司与骨折风险降低相关。